Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Acorda Therapeutics
(NQ:
ACOR
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Apr 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Acorda Therapeutics
< Previous
1
2
3
4
5
6
7
8
Next >
Why Is Acorda Therapeutics (ACOR) Stock Down 72% Today?
April 02, 2024
Acorda Therapeutics stock is falling hard on Tuesday after the company announced a bankruptcy filing and stalking horse bid agreement.
Via
InvestorPlace
Topics
Bankruptcy
Exposures
Financial
Legal
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
April 02, 2024
Via
Benzinga
Why VirTra Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
April 02, 2024
Shares of VirTra, Inc. (NASDAQ: VTSI) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter results.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
April 02, 2024
It's time to check out all of the biggest pre-market stock movers worth watching on with the winners and losers of Tuesday!
Via
InvestorPlace
Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
April 01, 2024
From
Acorda Therapeutics
Via
Business Wire
Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024
April 01, 2024
From
Acorda Therapeutics Acorda Therapeutics, Inc.
Via
Business Wire
Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024
March 25, 2024
From
Acorda Therapeutics
Via
Business Wire
Earnings Scheduled For April 1, 2024
April 01, 2024
Companies Reporting Before The Bell • Mach Natural Resources (NYSE:MNR) is projected to report quarterly earnings at $0.92 per share on revenue of $213.43 million.
Via
Benzinga
Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025
January 11, 2024
From
Acorda Therapeutics
Via
Business Wire
A Look Into Healthcare Sector Value Stocks
November 20, 2023
Via
Benzinga
Acorda Therapeutics Reports Third Quarter 2023 Financial Results
November 13, 2023
From
Acorda Therapeutics
Via
Business Wire
Acorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023
November 06, 2023
From
Acorda Therapeutics
Via
Business Wire
Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®
November 06, 2023
From
Acorda Therapeutics
Via
Business Wire
Earnings Scheduled For November 13, 2023
November 13, 2023
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.
Via
Benzinga
Acorda Therapeutics Inc. (NASDAQ: ACOR) Leading the Way in Thursday Trading Based on Percentage Gain
October 05, 2023
Via
Investor Brand Network
12 Health Care Stocks Moving In Wednesday's After-Market Session
October 04, 2023
Via
Benzinga
Overview Of Value Stocks In The Healthcare Sector
September 18, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
August 30, 2023
Via
Benzinga
5 Value Stocks To Watch In The Healthcare Sector
August 21, 2023
Via
Benzinga
Acorda Therapeutics Reports Second Quarter 2023 Financial Results
August 08, 2023
From
Acorda Therapeutics
Via
Business Wire
Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The Fighters™”
August 02, 2023
From
Acorda Therapeutics
Via
Business Wire
Acorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023
August 01, 2023
From
Acorda Therapeutics
Via
Business Wire
Tom Burns Elected to the Acorda Therapeutics Board of Directors
June 28, 2023
From
Acorda Therapeutics
Via
Business Wire
Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
June 26, 2023
From
Acorda Therapeutics
Via
Business Wire
Why Semtech Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
June 08, 2023
Gainers Airspan Networks Holdings Inc. (NYSE: MIMO) shares rose 50.5% to $0.20 in pre-market trading after dropping 5% on Wednesday.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
June 08, 2023
Pre-market stock movers are a hot topic with traders on Thursday as we go over the shares seeing the biggest movements this morning.
Via
InvestorPlace
Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split
June 02, 2023
From
Acorda Therapeutics
Via
Business Wire
Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split
May 31, 2023
From
Acorda Therapeutics
Via
Business Wire
Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
May 30, 2023
From
Acorda Therapeutics
Via
Business Wire
Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC
May 13, 2023
Bliss Biopharma may out-license global rights for its HER2 ADC to Eisai Pharma in a deal with a potential value of $2 billion. Also, Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to Dr....
Via
Talk Markets
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.